论文部分内容阅读
目的探讨噻托溴铵联合沙美特罗替卡松治疗稳定期C组D组慢性阻塞性肺疾病(COPD)的临床疗效。方法选取2013年1月一2014年1月福建医科大学福建省老年医院教学医院收治的稳定期C组D组COPD患者78例,随机分为试验组与对照组,各39例。试验组患者予以噻托溴铵联合沙美特罗替卡松治疗,对照组患者予以沙美特罗替卡松治疗。观察两组患者治疗前后临床疗效指标及不良反应发生情况。结果治疗前两组患者血氧分压(Pa O2)、二氧化碳分压(Pa CO2)、慢性阻塞性肺病评估测试(CAT)评分、第1秒用力呼气容积占预计值百分比(FEV1%pred)、第1秒用力呼气容积占肺活量百分比(FEV1/FVC%)、6min步行距离(6MWD)、圣·乔治医院呼吸问题调查问卷(SGRQ)评分比较,差异无统计学意义(P>0.05);治疗后试验组患者Pa O2高于对照组,Pa CO2、CAT评分、SGRQ评分低于对照组,6MWD大于对照组,差异有统计学意义(P<0.05),两组患者FEV1/FVC%、FEV1%pred比较,差异无统计学意义(P>0.05);两组患者均未发生严重不良反应。结论噻托溴铵联合沙美特罗替卡松治疗稳定期C组D组COPD的临床疗效显著,可改善患者临床症状,降低急性发作频率,提高生活质量及运动耐力,且不良反应小。
Objective To investigate the clinical efficacy of tiotropium combined with salmeterol and tacoceptus in the treatment of stable COPD patients with chronic obstructive pulmonary disease (COPD). Methods From January 2013 to January 2014, 78 patients with stable COPD in group D received treatment at Fujian Provincial Hospital of Aged Geriatrics, Fujian Medical University from January 2013 to January 2014, and were randomly divided into experimental group and control group, with 39 cases in each group. Patients in the test group were treated with tiotropium combined with salmeterol / fluticasone, and patients in the control group received salmeterol / fluticasone treatment. Before and after treatment, the clinical efficacy indexes and adverse reactions were observed. Results PaO2, PaCO 2, CAT, CAT and FEV 1% pred of the two groups before treatment were significantly higher than those of the control group (FEV1 / FVC%), 6MWD (6MWD) and SGRQ score in the 1st and 2nd quartile were significantly different between the two groups (P> 0.05). After treatment, the PaO 2 in the test group was higher than that in the control group, PaCO 2, CAT score and SGRQ score were lower than the control group, 6MWD was greater than the control group, the difference was statistically significant (P0.05), FEV1 / FVC%, FEV1 % pred comparison, the difference was not statistically significant (P> 0.05); two groups of patients did not occur serious adverse reactions. Conclusion The clinical efficacy of tiotropium combined with salmeterol and fluticasone in stable COPD group D is significant, which can improve the clinical symptoms, reduce the frequency of acute exacerbations, improve the quality of life and exercise tolerance, and the adverse reactions are small.